What is the latest BIOCON stock price?
The latest stored price for BIOCON is Rs 415.55 as of 2026-08-21.
gimli
BIOCON stock AI analysis
BIOCON Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
BIOCON LIMITED. is a mid-cap stock in Healthcare. This Gimli page shows the latest available BIOCON price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹415.55
1W return
-0.35%
1M return
-5.62%
3M return
-3.55%
6M return
+8.23%
1Y return
+16.16%
Market cap
₹67,291.31 cr
PE
165.58
PB
1.84
ROE
+1.26%
ROCE
+2.86%
RSI
43.90
Turnover
₹92.47 cr
Why it can matter in screens
- Momentum: BIOCON is below 50DMA, above 200DMA; RSI is 43.90.
- Returns: 1D +0.74%, 1W -0.35%, 1M -5.62%, 3M -3.55%, 1Y +16.16%.
- Trend levels: 52W high ₹447.15, 52W low ₹394.85, off high -7.07%.
- Liquidity: latest turnover is ₹92.47 cr; volume vs 20D is +0.63%.
- Valuation/profitability: PE 165.58, PB 1.84, ROE +1.26%, ROCE +2.86%.
- Growth: 3Y sales CAGR +15.34%, 3Y profit CAGR -5.89%.
Quick Answers
Is BIOCON above its 50DMA and 200DMA?
BIOCON is below 50DMA, above 200DMA. The latest 50DMA is 422.81 and the latest 200DMA is 395.21.
What are BIOCON PE, ROE and ROCE?
BIOCON has PE 165.58, ROE +1.26%, and ROCE +2.86% in Gimli's latest available snapshot.
How has BIOCON performed recently?
BIOCON has returned -5.62% over 1 month, -3.55% over 3 months, and +16.16% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 689.30 cr | 125.60 cr | 52.20 cr | 0.87 |
| 2026-03-31 | 4,484.30 cr | 992.40 cr | 125.90 cr | 0.79 |
| 2025-12-31 | 4,173.00 cr | 657.40 cr | 143.80 cr | 1.08 |
| 2025-09-30 | 4,262.50 cr | 916.50 cr | 84.50 cr | 0.66 |
| 2025-06-30 | 3,910.10 cr | 828.60 cr | 31.40 cr | 0.26 |
| 2025-03-31 | 4,358.10 cr | 1,135.50 cr | 344.50 cr | 2.88 |
| 2024-12-31 | 3,773.00 cr | 804.70 cr | 25.10 cr | 0.21 |
| 2024-09-30 | 3,545.00 cr | 743.90 cr | -16.00 cr | -0.13 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 16,779.90 cr | 3,394.90 cr | 385.60 cr | 2.82 |
| 2025-03-31 | 15,052.20 cr | 4,471.00 cr | 1,013.30 cr | 8.46 |
| 2024-03-31 | 14,195.80 cr | 4,068.40 cr | 1,022.50 cr | 8.55 |
| 2023-03-31 | 10,934.10 cr | 2,429.20 cr | 462.70 cr | 3.88 |
| 2022-03-31 | 1,925.40 cr | 1,864.90 cr | 86.10 cr | 0.72 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 63,650.60 cr | 2,416.50 cr | 15,434.10 cr | 36,621.50 cr |
| 2025-03-31 | 58,797.30 cr | 3,226.70 cr | 18,362.00 cr | 27,712.50 cr |
| 2024-03-31 | 56,070.70 cr | 1,233.40 cr | 16,276.70 cr | 25,274.80 cr |
| 2023-03-31 | 52,042.80 cr | 1,323.20 cr | 18,018.80 cr | 22,488.80 cr |
| 2022-03-31 | 20,394.00 cr | 662.60 cr | 5,146.60 cr | 9,470.00 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,994.00 cr | 82.30 cr | n/a |
| 2025-03-31 | 4,061.20 cr | 1,717.90 cr | n/a |
| 2024-03-31 | 2,953.90 cr | 1,022.30 cr | n/a |
| 2023-03-31 | 1,852.50 cr | 126.20 cr | n/a |
| 2022-03-31 | 1,176.60 cr | -748.20 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +44.68% | +8.14% | +23.38% | +15.47% | +23.75% | +0.00% |
| 2026-06-29 | +44.68% | +8.16% | +23.37% | +15.49% | +23.74% | +0.00% |
| 2026-03-31 | +44.91% | +7.52% | +24.07% | +16.53% | +23.41% | +0.00% |
| 2026-01-14 | +44.91% | +7.14% | +24.16% | +17.03% | +23.69% | +0.00% |
| 2026-01-05 | +48.27% | +6.56% | +19.65% | +12.17% | +25.42% | +0.00% |
| 2025-12-31 | +54.45% | +7.39% | +21.71% | +13.75% | +16.33% | +0.00% |
| 2025-09-30 | +54.45% | +6.61% | +22.10% | +14.13% | +16.69% | +0.00% |
| 2025-06-30 | +54.45% | +6.04% | +22.82% | +15.24% | +16.50% | +0.00% |
| 2025-06-19 | +54.45% | +7.00% | +21.45% | +13.82% | +16.91% | +0.00% |
| 2025-03-31 | +60.64% | +5.66% | +15.72% | +8.77% | +17.76% | +0.00% |
| 2024-12-31 | +60.64% | +5.66% | +15.37% | +8.58% | +18.12% | +0.00% |
| 2024-09-30 | +60.64% | +5.93% | +14.44% | +7.97% | +18.75% | +0.00% |
| 2024-06-30 | +60.64% | +5.90% | +14.30% | +8.69% | +18.89% | +0.00% |
| 2024-03-31 | +60.64% | +5.63% | +13.68% | +8.57% | +19.73% | +0.00% |
| 2023-12-31 | +60.64% | +6.55% | +14.51% | +9.31% | +17.96% | +0.00% |
| 2023-09-30 | +60.64% | +7.96% | +14.08% | +8.26% | +16.92% | +0.00% |
| 2023-06-30 | +60.64% | +9.52% | +12.59% | +7.47% | +16.76% | +0.00% |
| 2023-03-31 | +60.64% | +10.20% | +11.90% | +7.19% | +16.71% | +0.00% |
| 2022-12-31 | +60.64% | +14.42% | +8.63% | +3.95% | +15.73% | +0.00% |
| 2022-09-30 | +60.64% | +15.79% | +7.76% | +3.21% | +15.18% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze BIOCON. with valuation, momentum and industry peers
- Compare BIOCON with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare BIOCON with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.